Clinical Trial Update: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma [Phase 3]

View source ↗

Summary

Phase 3 trial examining combination chemotherapy with or without temsirolimus in intermediate-risk rhabdomyosarcoma; active/not recruiting with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Rhabdomyosarcoma
• Botryoid-type Embryonal Rhabdomyosarcoma
• Embryonal Rhabdomyosarcoma
• Rhabdomyosarcoma
• Sclerosing Rhabdomyosarcoma
• Spindle-cell Rhabdomyosarcoma

Drugs mentioned

• Chemotherapy (combination)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-01